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EVIDENCE-BASED MEDICINE — WHAT’S NEW?
Pharmacotherapy after the ESC Congress 2018 in Munich  
— which questions have been answered?
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Abstract
During 5 hot-line sessions at the ESC Congress 2018 in Munich several significant clinical trials’ results were published. 
Authors selected top five trials answering the most important questions in pharmacotherapy of cardiovascular diseases.
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of coronary death 10–20%). So far, the effectiveness of 
acetylsalicylic acid has only been proven in secondary pre-
vention. Despite the lack of clear evidence for the benefit 
of prophylactic effects of ASA administration, it is a quite 
common practice to include ASA in primary prevention 
in patients with indirect cardiovascular risk. It is worth 
stressing that this kind of practice is not clearly written in 
European guidelines and is quite controversial.
The ARRIVE study was a multi-center, prospective, 
double-blind, randomized study in which the studied 
group were individuals receiving 100 mg of ASA/day and 
the control group was a placebo. The study was conduc-
ted in 501 centers in 7 countries and included a total of 
12,546 patients with indirect cardiovascular. After ran-
domization, they were divided into 2 groups at a ratio of 
almost 1 to 1. The observation median was 60 months. 
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At the 5 hot-line session in the course of this year’s 
Congress of the European Society of Cardiology, results 
of several interesting clinical trials were presented. The 
authors decided to present five works of the most impor-
tant value in their subjective assessment. The works were 
presented from the perspective of current state of know-
ledge and the questions which practicing physicians have.
The first two hot-line sessions were dominated by 
research about one of the oldest drugs in use today — 
acetylsalicylic acid (ASA). This topic was presented by the 
presentation of (combined with a simultaneous publication 
in the “The Lancet”) of the results of the ARRIVE (Aspirin 
to Reduce Risk of Initial Vascular Events) study [1].The 
main aim of the study was to analyze the effectiveness 
and safety of aspirin in primary prevention in patients 
with moderate risk of cardiovascular incident (10-year risk 
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Patients with diabetes or high risk of bleeding were not 
included in the study. The main efficacy measurement was 
the time to the first occurrence of a complex endpoint in 
the form of cardiovascular death, myocardial infarction, 
unstable angina, stroke or transient cerebral ischemia. 
Safety Endpoints were the occurrence of hemorrhagic 
incidents or other adverse events. The results of the study 
did not bring any expected breakthrough because of the 
lack of impact on the effectiveness of prevention. The 
main endpoint occurred in 269 patients from the studied 
group (4.29%) and in 281 patients from the control group 
(4.48%) — hazard ratio (HR) = 0.96; 95% confidence 
interval (CI) 0.81–1.13, p = 0.6038. Safety results are 
worth emphasizing, as the risk of bleeding with use of ASA 
increased more than two-fold: in the study group gastroin-
testinal bleeding occurred in 61 patients (0.97%) and in 
the control group in 29 patients (0.46%) — HR = 2.11; 95% 
CI 1.36–3.28, p = 0.0007. Other adverse events occurred 
with similar frequency in both groups. During the obser-
vation, 321 deaths were observed (160 in the ASA group 
— 2.55%, 161 in the placebo group — 2.57%) and therefore 
much less frequently than expected — it seems that the 
scales which are used, overestimate the risk in patients 
treated nowadays. Since the risk of bleeding when using 
ASA is constant, this explains the lack of “net”; benefits.
Therefore, both the researchers and the reviewers 
pointed out that the results of the study more accurately 
reflect the use of ASA in individuals with low cardiovascular 
risk and contrary to the assumptions do not refer to an 
indirect risk group. ASA therapy confirmed a significant 
reduction in the risk of myocardial infarction by 45–47% in 
a subgroup of patients with good therapeutic cooperation 
(> 60% of doses taken, 7702 individuals). The second 
study on acetylsalicylic acid, the results of which were 
presented and published in “The New England Journal of 
Medicine” on the same day, there was an ASCEND (A Study 
of Cardiovascular Events in Diabetes: Characteristics of 
a randomized trial of aspirin and of omega-3 fatty acid 
supplementation in 15,480 people with diabetes) trial 
[2, 3]. This study was designed to compare the effects of 
aspirin at a dose of 100 mg/day and omega-3 fatty acids 
at a dose of 1 g/day in people with diabetes mellitus as 
a part of primary prevention. The endpoints of the study 
were defined as follows: for efficacy, the first episode of 
a significant hemorrhagic cardiovascular incident (myocar-
dial infarction, stroke or transient ischemic attack or death 
from any other vascular cause); for safety, the episode of 
significant bleeding (intracranial bleeding, bleeding into 
the eye which threatens loss of vision, gastrointestinal 
bleeding or other serious bleeding requiring intervention). 
What is worth emphasizing, the secondary endpoint for 
ASA was the occurrence of colorectal cancer.
ASCEND was a prospective, randomized study using 
placebo as a comparator for which 15,480 patients were 
recruited. The average observation time was 7.4 years. The 
results, although promising, also did not provide a defi-
nitive answer about the use of aspirin. The main endpoint 
occurred 12% less frequently when using ASA than in the 
control population: 658 (8.5%) vs. 743 (9.6%), p = 0.01. 
At the same time, patients undergoing ASA treatment were 
more likely to have serious bleeding by 29%: 314 (4.1%) 
vs. 245 (3.2%), p = 0.003, with a clear predominance of 
gastrointestinal bleeding and other non-cranial sites. In 
terms of oncological observation, there were no statis-
tically significant differences. The results of this study 
confirm that in patients with diabetes mellitus without 
cardiovascular complications, ASA may reduce the risk 
of their occurrence, however, the benefits of this action 
are in the vast majority of cases balanced by a negative 
increase in the risk of serious bleeding.
Analysis of the use of omega-3 fatty acids in primary 
prevention in patients with diabetes mellitus did not show 
any benefit of such action compared to placebo. This calls 
into question the sense of their use in everyday practice 
as a dietary supplement. At the same time, the authors 
emphasize the sense of their use as a therapeutic additive 
in patients with severe hypertriglyceridemia.
Despite the differences in terms of subject matter 
Monday’s hotline session was rich in interesting pharma-
cological research, with particular attention paid to the 
ATTR-ACT (The Transthyretin Amyloidosis Cardiomyopa-
thy Clinical Trial). Presentation of the results (as well as 
a publication in “The New England Journal of Medicine”; 
entitled “Tafamidis Treatment for Patients with Transthy-
retin Amyloid Cardiomyopathy”) [4] were preceded by an 
introduction to the subject of a relatively rarely mentioned 
disease called cardiomyopathy in the course of amyloidosis 
with transtretin mutation (genetically conditioned storage 
disease which is described as an accumulation of deposits 
of abnormally shaped transtretin in the myocardium). The 
disease most often manifests itself in the 6th decade of 
life. The authors emphasize that the disease can occur 
quite often (in about 13% of patients with heart failure 
with preserved ejection fraction) and scintigraphy is one 
of the non-invasive diagnostic methods used. Prognosis 
is worth noting — the median time of survival from diag-
nosis varies between 2.5 and 3.6 years depending on the 
subtype of mutation.
ATTR-ACT was a multi-center, international, parallel de-
signed, double-blinded, randomized, phase 3 clinical trial 
with placebo as control over the treatment strategy. The 
main aim of the authors was to investigate the influence of 
tafamidis on the natural course of the disease. Tafamidis 
was registered for the treatment of a pathomechanically 
similar disease so called transthyretin familial amyloid 
polyneuropathy. It has been proven that by binding itself, 
instead of thyroxine with transthyretin, it stabilizes it in the 
form of a harmless tetramer, which significantly inhibits 
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the development of the disease. In the presented study 
it was decided to verify the legitimacy of administration 
of this drug to patients with cardiomyopathic form of the 
disease. The study included 441 patients with the above 
diagnosis. 3 subpopulations were designed in the ratio 
of 2:1:2 respectively receiving: 80 mg of tafamidis daily, 
20 mg of tafamidis daily and a placebo for 30 months. 
The main endpoints were: total mortality and frequency 
of hospitalizations related to cardiovascular diseases. Se-
condary endpoints were defined as a change in the results 
of the 6-minute walk test after 30 months in relation to 
the randomization and a change in the Kansas City Car-
diomyopathy Questionnaire-Overall Summary (KCCQ-OS).
The results seem promising — in the study group (80 mg 
+ 20 mg in total) the number of deaths from all causes 
turned out to be significantly lower than in the placebo 
group: 29.5% vs. 42.9%, HR = 0.70; 95% CI 0.56–0.96, 
p < 0.001. The frequency of hospitalizations reported in the 
study group was also lower by 32%, p < 0.001. The group 
treated with tafamidis achieved better results in the qua-
lity of life questionnaire and in the 6-minute march tests 
(for both analyses p < 0.001). Importantly, the authors 
point out that the number and type of adverse effects in 
both groups is at a similar level. During the next hot-line 
sessions, more excellent studies were presented. In the 
beginning, the results of the FREED study (Febuxostat 
for Cerebral and CaRdiorenovascular Events PrEvEntion 
StuDy) were presented. [5] This trial was designed as 
a multi-center, prospective, randomized open-label study 
with a blinded endpoint and two parallel arms to investi-
gate the potential of febuxostat (a selective xanthin oxi-
dase inhibitor), which reduces uric acid concentration in 
the blood, in terms of prevention of brain, cardiovascular 
and renal incidents when compared to standard therapy.
The study included 1070 patients aged 65 and above 
with diagnosed hyperuricemia (serum uric acid concentra-
tion between 7.0 and 9.0 mg/dl). The observation period 
lasted 36 months. In the study group there were 537 pa-
tients who took increasing doses of febuxostat (from 10 to 
40 mg/day). In the control group allopurinol at a dose of 
100 mg was administered only to those individuals in 
which significantly elevated serum uric acid levels were 
detected. In both groups decreasing of concentration of 
uric acid below 2.0 mg/dl was avoided. All patients had 
an increased cardiovascular risk in regard to the control 
of known risk factors. The main complex endpoint is de-
fined as the occurrence of a cerebral, cardiovascular or 
renal incident or any new disease or even death of any 
cause. Febuxostat significantly reduced uric acid levels 
to an average of 4.5 mg/dl compared to a group without 
this drug: 6.76 mg/dl — the effect was observable after 
approx. 8–12 weeks of therapy.
In terms of drug efficacy in prevention of the occurrence 
of a complex endpoint, the results are promising — 23.3% 
of individuals in the group taking the drug and 28.7% in the 
group without the drug. Therefore, a 25% lower risk of the 
target endpoint in the group receiving the test substance 
was noted — HR = 0.75, 95% CI 0.592–0.950, p = 0.017, 
mainly due to reduced risk of kidney failure — study group 
(16.2%) vs, control group (20.5%) — HR = 0.745, 95% CI 
0.562–0.987, p = 0.041. However, there were no statisti-
cally significant differences in the incidence of deaths from 
any cause, risk of a cerebrovascular incident or coronary 
disease. FREED was a small study and in the context of 
an earlier CARES trial (where an increased risk of death 
was observed in patients treated with febuxostat vs. 
allopurinol) febuxostat does not show protection against 
cardiovascular complications.
It certainly cannot be treated as an encouragement 
for broad treatment of asymptomatic hyperuricaemia 
with a purpose of prevention — the reduction of uric acid 
should be reserved for the treatment of symptomatic gout 
according to world guidelines. For the patient listeners, the 
last hotline session had one of the most interesting studies 
presented during this year’s ESC Congress — POET (Partial 
Oral versus Intravenous Antibiotic Treatment of Endocardi-
tis), from the perspective of a practicing physician. At the 
same time, it was published in “The New England Journal 
of Medicine” [6], The studies aim was to explain, whether 
it is possible to accept a less strict therapeutic strategy 
of the treatment of left-sided infective endocarditis rather 
than the 6-week antibiotic intravenous therapy in hospital 
settings which is recommended by the guidelines. The 
trial was designed to assess the efficacy and safety of the 
transition from intravenous to oral therapy, after 2 weeks 
of standard treatment with the intention of stabilizing the 
clinical status of the patients.
POET was a Danish multicenter, randomized, prospec-
tive study of equivalence type, in which 400 hemodynam-
ically stable patients with left-sided infective endocarditis 
were included. The patients selected had their diagnosis 
placed on the basis of blood cultures where methicil-
lin-sensitive streptococci, enterococci or staphylococci 
were cultured.
All patients received intravenous antibiotic therapy for 
at least 10 days. Patients were randomized to 2 groups — 
still treated intravenously (199 people) and with continued 
oral treatment (201 people). If such a possibility existed, 
after the patients were set up on oral treatment, they were 
discharged and controlled in out-patient clinics. The main 
endpoint was total mortality, unplanned cardiac surgery, 
thromboembolic incidents or recurrence of bacteremia 
with the primary pathogen from the time of randomization 
to 6 months after the end of pharmacotherapy. It seems 
that the type of antibiotics used (selected based on phar-
macokinetic properties) and a thorough echocardiographic 
exam (also transesophageal) are relevant to confirm if 
there is need of further intensive parenteral treatment 
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before the possibility of oral treatment is introduced. It is 
also far more important to check on patients more often 
if they are treated in outpatient conditions rather than in 
actual conditions.
However, despite the concerns raised by the reviewers, 
the results of the presented study were rewarded with 
thunderous applause, as they seem to be extremely opti-
mistic. The median of primary intravenous treatment was 
19 days in the group treated with standard therapy and 
17 days in the target group treated orally (p = 0.48). The 
main complex endpoint occurred in 24 (12.1%) patients in 
the group treated intravenously and in 18 (9.0%) patients 
treated according to the study protocol — the difference 
between the groups was 3.1 percentage points, 95% CI 
–3.4–9.6, p = 0.40 — which corresponds to the fulfilment 
of the equivalence criterion — so the oral treatment stra-
tegy seems to be no worse than the standard long-term 
intravenous treatment recommended in the European 
and American guidelines. These data are encouraging 
and pave the way for further exploring the possibility of 
less restrictive treatment of patients with mild infective 
endocarditis.
Streszczenie
W trakcie 5 sesji hot-line Kongresu ESC 2018 w Monachium zaprezentowano wyniki kilku istotnych badań klinicznych. 
Autorzy wybrali subiektywnie 5 najważniejszych, odpowiadających na kluczowe pytania z zakresu farmakoterapii chorób 
układu sercowo-naczyniowego.
Słowa kluczowe: farmakoterapia, Kongres ESC 2018, badania kliniczne, leki, ryzyko sercowo-naczyniowe,  
śmiertelność, bezpieczeństwo, kwas acetylosalicylowy, infekcyjne zapalenie wsierdzia
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